SurgeCare provides an end-to-end platform that transforms complex multiomic biological data into clinically actionable insights for precision health applications. Their proprietary Stabl technology extracts robust biological fingerprints to enable the discovery of new, interpretable biomarkers. The company offers products like PreCyte SSI, which uses these biomarkers to predict the risk of postoperative complications in clinical settings.
Funding
$10.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Surgical complications represent a significant risk, affecting a substantial percentage of patients and leading to increased healthcare costs and prolonged recovery times. Current methods for predicting these complications often lack the precision needed to personalize pre-operative care effectively. This can result in suboptimal surgical decision-making and a higher incidence of adverse outcomes.
Solution
Surge offers PreCyte, a technology that analyzes a patient's immune system from a single blood sample to predict the risk of post-operative complications. PreCyte utilizes mass cytometry to deeply profile the immune system and machine learning algorithms to identify predictive biomarkers. This allows for a more accurate assessment of individual patient risk, enabling clinicians to personalize pre-operative care pathways and optimize surgical strategies. By providing actionable insights derived from complex biological data, PreCyte aims to reduce the incidence of surgical complications and improve patient outcomes.
Target Audience
The primary target audience includes surgeons, hospitals, and healthcare providers seeking to reduce post-operative complications and improve patient outcomes through personalized surgical planning.
Features
- Mass cytometry analysis of immune cells from a single blood sample
- Proprietary Stabl algorithm for biomarker discovery and identification
- Machine learning models for predicting post-operative complication risk
- PreCyte SSI product line translating predictive biomarkers into clinical tools
- Actionable insights for personalized pre-operative care